Actively Recruiting
Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-27
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting information on the use of redifferentiating medications as a standard treatment for patients with radioactive iodine (RAI)-refractory thyroid cancer. This study is a registry designed to learn more about how these medications are used in routine clinical care for this condition. It is an observational study focused on patients who have thyroid cancer that does not respond well to RAI treatment. Participants will undergo follow-up visits at intervals determined by their usual clinical care. During these visits, researchers will record how well patients tolerate the redifferentiating medications and any adverse events they experience. The study includes patients receiving these agents as part of their regular treatment, both prospectively and retrospectively, but excludes those receiving such agents within other clinical trials. Participants will be monitored for adverse events at every visit over a period of two years. Researchers will collect and review data on medication tolerance and side effects during these follow-up appointments. This ongoing observation aims to provide a clearer picture of outcomes for patients treated with redifferentiation agents in usual care settings.
CONDITIONS
Brief Title
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years or older at time of consent
- Diagnosed with radioactive iodine-refractory thyroid cancer or unlikely to respond to radioactive iodine
- Receiving redifferentiation agents before planned diagnostic or therapeutic radioactive iodine as part of routine clinical care
- Patients who have never received redifferentiation agents outside of a clinical trial or who received them during a clinical trial but now are treated as part of routine care
- Patients previously treated with redifferentiation agents in clinical care willing to provide retrospective and prospective data
You will not qualify if you...
- Patients receiving redifferentiation agents before radioactive iodine as part of a prospective clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants who undergo routine care with redifferentiation agents are observed. Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
Visits at intervals per usual clinical practice
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
L
Laura Boucai, MD
A
Alan Ho, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here